146 related articles for article (PubMed ID: 25111818)
1. The role of mutation of metabolism-related genes in genomic hypermethylation.
Waterfall JJ; Killian JK; Meltzer PS
Biochem Biophys Res Commun; 2014 Dec; 455(1-2):16-23. PubMed ID: 25111818
[TBL] [Abstract][Full Text] [Related]
2. Isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH), fumarate hydratase (FH): three players for one phenotype in cancer?
Laurenti G; Tennant DA
Biochem Soc Trans; 2016 Aug; 44(4):1111-6. PubMed ID: 27528759
[TBL] [Abstract][Full Text] [Related]
3. The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms.
Schaefer IM; Hornick JL; Bovée JVMG
Lab Invest; 2018 Apr; 98(4):414-426. PubMed ID: 29339836
[TBL] [Abstract][Full Text] [Related]
4. Metabolic alteration in tumorigenesis.
Yang H; Xiong Y; Guan K
Sci China Life Sci; 2013 Dec; 56(12):1067-75. PubMed ID: 24114443
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors.
Xiao M; Yang H; Xu W; Ma S; Lin H; Zhu H; Liu L; Liu Y; Yang C; Xu Y; Zhao S; Ye D; Xiong Y; Guan KL
Genes Dev; 2012 Jun; 26(12):1326-38. PubMed ID: 22677546
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors.
Hoekstra AS; de Graaff MA; Briaire-de Bruijn IH; Ras C; Seifar RM; van Minderhout I; Cornelisse CJ; Hogendoorn PC; Breuning MH; Suijker J; Korpershoek E; Kunst HP; Frizzell N; Devilee P; Bayley JP; Bovée JV
Oncotarget; 2015 Nov; 6(36):38777-88. PubMed ID: 26472283
[TBL] [Abstract][Full Text] [Related]
7. Revisiting the TCA cycle: signaling to tumor formation.
Raimundo N; Baysal BE; Shadel GS
Trends Mol Med; 2011 Nov; 17(11):641-9. PubMed ID: 21764377
[TBL] [Abstract][Full Text] [Related]
8. Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites.
Menendez JA; Alarcón T; Joven J
Cell Cycle; 2014; 13(5):699-709. PubMed ID: 24526120
[TBL] [Abstract][Full Text] [Related]
9. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer.
King A; Selak MA; Gottlieb E
Oncogene; 2006 Aug; 25(34):4675-82. PubMed ID: 16892081
[TBL] [Abstract][Full Text] [Related]
10. Targeting cancer metabolism.
Teicher BA; Linehan WM; Helman LJ
Clin Cancer Res; 2012 Oct; 18(20):5537-45. PubMed ID: 23071355
[TBL] [Abstract][Full Text] [Related]
11. Cancer. Puzzling patterns of predisposition.
Pollard PJ; Ratcliffe PJ
Science; 2009 Apr; 324(5924):192-4. PubMed ID: 19359573
[No Abstract] [Full Text] [Related]
12. Metabolic enzymes as oncogenes or tumor suppressors.
Thompson CB
N Engl J Med; 2009 Feb; 360(8):813-5. PubMed ID: 19228626
[No Abstract] [Full Text] [Related]
13. Inborn and acquired metabolic defects in cancer.
Frezza C; Pollard PJ; Gottlieb E
J Mol Med (Berl); 2011 Mar; 89(3):213-20. PubMed ID: 21301796
[TBL] [Abstract][Full Text] [Related]
14. Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma.
Richter S; Gieldon L; Pang Y; Peitzsch M; Huynh T; Leton R; Viana B; Ercolino T; Mangelis A; Rapizzi E; Menschikowski M; Aust D; Kroiss M; Beuschlein F; Gudziol V; Timmers HJ; Lenders J; Mannelli M; Cascon A; Pacak K; Robledo M; Eisenhofer G; Klink B
Genet Med; 2019 Mar; 21(3):705-717. PubMed ID: 30050099
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial dysfunctions in cancer: genetic defects and oncogenic signaling impinging on TCA cycle activity.
Desideri E; Vegliante R; Ciriolo MR
Cancer Lett; 2015 Jan; 356(2 Pt A):217-23. PubMed ID: 24614286
[TBL] [Abstract][Full Text] [Related]
16. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.
Losman JA; Kaelin WG
Genes Dev; 2013 Apr; 27(8):836-52. PubMed ID: 23630074
[TBL] [Abstract][Full Text] [Related]
17. The functional roles of TCA cycle metabolites in cancer.
Eniafe J; Jiang S
Oncogene; 2021 May; 40(19):3351-3363. PubMed ID: 33864000
[TBL] [Abstract][Full Text] [Related]
18. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations.
Pollard PJ; Brière JJ; Alam NA; Barwell J; Barclay E; Wortham NC; Hunt T; Mitchell M; Olpin S; Moat SJ; Hargreaves IP; Heales SJ; Chung YL; Griffiths JR; Dalgleish A; McGrath JA; Gleeson MJ; Hodgson SV; Poulsom R; Rustin P; Tomlinson IP
Hum Mol Genet; 2005 Aug; 14(15):2231-9. PubMed ID: 15987702
[TBL] [Abstract][Full Text] [Related]
19. Metabolic reprogramming and epithelial-to-mesenchymal transition in cancer.
Sciacovelli M; Frezza C
FEBS J; 2017 Oct; 284(19):3132-3144. PubMed ID: 28444969
[TBL] [Abstract][Full Text] [Related]
20. Genetically-defined metabolic reprogramming in cancer.
Mullen AR; DeBerardinis RJ
Trends Endocrinol Metab; 2012 Nov; 23(11):552-9. PubMed ID: 22858391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
